-
2024-520117-50-00
4
Atopic Dermatitis
-
2025-523461-17-01
5
LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
-
2023-503766-24-00
11
2026-05-26
Moderate to Severe Plaque Psoriasis
-
2025-522255-25-00
5
2026-05-18
Fallopian Tube Neoplasms
-
2025-524498-17-00
10
2026-05-08
Pretreated Unresectable Locally Advanced or Metastatic human epidermal
-
2025-520466-22-00
5
2026-04-29
Advanced Platinum-resistant Epithelial Ovarian Cancer
-
2025-521884-12-00
5
2026-03-19
First line triple-negative breast cancer (TNBC)
-
2025-521514-26-00
5
2026-01-26
Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
-
2024-517968-36-00
5
2025-07-08
non-small cell lung cancer
-
2024-511166-36-00
5
2025-06-13
Moderate to Severe Plaque Psoriasis
-
2024-513317-12-00
5
2025-02-05
Pancreatic cancer
-
2024-514135-17-00
5
2024-11-28
Immunoglobulin A Nephropathy
-
2023-503630-44-00
10
2024-11-20
Treatment of moderate-to-severe Atopic dermatitis
-
2022-501606-35-01
11
2024-02-21
Platinum-sensitive epithelial ovarian, fallopian tube, or primary
peri
-
2022-500273-14-00
10
2023-07-17
Atherosclerotic cardiovascular disease in patients with ESKD
-
2023-506548-18-00
10
2022-11-10
Dermatitis atopic
-
2023-505749-14-00
5
2022-03-20
c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
-
2024-518777-34-00
5
2026-02-11
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2025-520825-19-00
5
2025-12-16
IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as
Ber
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2025-521281-97-00
5
2025-12-02
Non-Small Cell Lung Cancer (NSCLC)
-
2024-517553-26-00
5
2025-11-12
Advanced ALK-positive non-small cell lung cancer (NSCLC)
-
2024-520190-12-00
5
2025-11-10
Breast Cancer: triple negative breast cancer (TNBC) and hormone recept